NEWARK, Del, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The aortic endograft market is expected to grow at a compound annual growth rate (CAGR) of 4.9% during the forecast period, from an estimated valuation ...
A 93-year-old Bronx man underwent implantation of a new stent graft at NewYork-Presbyterian Hospital. The new stent graft was implanted under an FDA-approved clinical trial protocol. The stent graft ...
Direct visualization of an endograft represents a rare and potentially precarious finding during surgical exploration. The exposed endograft poses an immediate hemorrhagic risk and a long-term risk of ...
During an 8-year period, 355 patients underwent endovascular repair of mainly true (97%) infrarenal aneurysms. After a mean follow-up of 48 months, 11 (3.1%) patients required conversion to open ...
While rare, endograft infection is increasing in frequency after endovascular abdominal aortic aneurysm repair (EVAR) or thoracic endovascular aneurysm repair (TEVAR), carrying with it a high risk of ...
IRVINE, Calif., Endologix, developer and marketer of innovative treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX ® 2 Bifurcated Endograft ...
IRVINE, Calif.--(BUSINESS WIRE)-- Transforming the treatment of aortic disorders, Endologix® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S.
The global aortic endograft industry was valued at around USD 3,255.5 million in 2023 and is anticipated to exhibit a CAGR of 4.9% over the forecast period. Accordingly, total market revenue is set to ...
Boston, MA (May 1, 2021) - Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in ...
Please provide your email address to receive an email when new articles are posted on . The FDA updated a prior safety alert to add that two additional endograft systems for repair of abdominal aortic ...
Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results